# A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07093970/  
OnCo record `nct07093970` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MRG006A in advanced solid tumours, run by Lepu Biopharma Co., Ltd., now recruiting.

## Summary

A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07093970 by Lepu Biopharma Co., Ltd., with 343 participants planned, started 2024-07-24 and due to reach its primary completion in 2027-12. Interventions recorded: MRG006A.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07093970
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Multi-center, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of MRG006A in Patients With Advanced Solid Tumors
- Sponsor: Lepu Biopharma Co., Ltd.
- Enrolled: 343

## Sources

- ClinicalTrials.gov NCT07093970: https://clinicaltrials.gov/study/NCT07093970

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Lepu Biopharma](https://onco.cc/companies/lepu-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct07093970.json